Comparison of clinical studies of salbutamol
| Route | Reference | Sample size | Dose | Mean initial K (mmol/l) | Peak reduction in K (mmol/l) | Time of maximal action (min) | Duration of effect (min) |
|---|---|---|---|---|---|---|---|
| *Excluded non-responders from analysis, †2.5 mg if <25 kg; 5 mg if >25 kg. IV = intravenous, Neb = nebulised. | |||||||
| IV | 4 | 13 | 4 μg/kg | 6.7 | 1.48 | 40 | >120 |
| IV | 5 | 24 | 0.5 mg | 7.0 | 1.4 | 30 | >360 |
| IV | 6 | 15 | 0.5 mg | 5.53 | 0.92* | 30 | >180 |
| IV | 8 | 17 | 4 μg/kg | 7.02 | 1.32 | 40 | >120 |
| IV | 9 | 17 | 0.5 mg | 5.7 | 0.95* | 30 | >180 |
| IV | 11 | 24 | 0.5 mg | 7.0 | 1.4 | 30 | >360 |
| IV | 14 | 15 | 5 μg/kg | 6.6 | 1.69 | 120 | >180 |
| IV | 15 | 11 | 4 μg/kg | 5.6 | 0.87 | 30 | 120 |
| Neb | 2 | 10 | 10 mg | 5.93 | 0.62 | 90 | >120 |
| Neb | 2 | 10 | 20 mg | 5.81 | 0.98 | 90 | >120 |
| Neb | 6 | 15 | 10 mg | 5.66 | 0.85* | 90 | >180 |
| Neb | 7 | 5 | 10 mg | 4.29 | 0.53 | 60 | >60 |
| Neb | 9 | 17 | 10 mg | 5.8 | 0.88* | 90 | >180 |
| Neb | 10 | 12 | 20 mg | 5.56 | 0.66 | 60 | >60 |
| Neb | 13 | 10 | 15 mg | 6.5 | 0.9 | 30 | >360 |
| Neb | 15 | 11 | 2.5/5 mg† | 5.9 | 0.61 | 30 | >300 |
| Neb | 16 | 9 | 15 mg | 5.99 | 0.57 | 60 | >60 |